OTCMKTS:NXNND - Nexeon Medsystems Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
$9.50 0.00 (0.00 %)
(As of 07/25/2018)
Previous Close$9.50
Today's Range$8.00 - $9.50
52-Week Range$4.48 - $35.00
Volume1,144 shs
Average Volume348 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

Receive NXNND News and Ratings via Email

Sign-up to receive the latest news and ratings for NXNND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NXNND
CUSIPN/A
CIKN/A
Phone844-919-9990

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Nexeon Medsystems (OTCMKTS:NXNND) Frequently Asked Questions

What is Nexeon Medsystems' stock symbol?

Nexeon Medsystems trades on the OTCMKTS under the ticker symbol "NXNND."

Has Nexeon Medsystems been receiving favorable news coverage?

News articles about NXNND stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nexeon Medsystems earned a news impact score of 1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are some of Nexeon Medsystems' key competitors?

Who are Nexeon Medsystems' key executives?

Nexeon Medsystems' management team includes the folowing people:
  • Mr. William Rosellini M.B.A., J.D., MBA, Chairman & CEO (Age 38)
  • Mr. Brian Blischak M.B.A., M.S., Pres & Chief Commercial Officer (Age 53)
  • Mr. Christopher R. Miller, Chief Financial Officer (Age 48)
  • Mr. Daniel Powell, VP of Sales & Marketing (Age 43)
  • Dr. Emily Hamilton Rosellini, Director of Emerging Therapy for NXPROC (Age 37)

What is Nexeon Medsystems' stock price today?

One share of NXNND stock can currently be purchased for approximately $9.50.

What is Nexeon Medsystems' official website?

The official website for Nexeon Medsystems is http://www.nexeonmed.com.

How can I contact Nexeon Medsystems?

Nexeon Medsystems' mailing address is 1910 PACIFIC AVENUE SUITE 20000, DALLAS TX, 75201. The company can be reached via phone at 844-919-9990 or via email at [email protected]


MarketBeat Community Rating for Nexeon Medsystems (OTCMKTS NXNND)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about Nexeon Medsystems and other stocks. Vote "Outperform" if you believe NXNND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXNND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel